Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (131-140 of 274) with videos related to

Pageof 28
Sort By:
Plos One|February 2, 2013
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsKatie Stone, Emily Woods, Susann M Szmania, et al.
American Journal of Hematology|August 7, 2024
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 24, 2025
The Involvement of PI3K-Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease-Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified SubtypesTomoka Haratake, Midori Filiz Nishimura, Asami Nishikori, et al.
Blood Cancer Journal|January 6, 2026
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myelomaToshali Pandey, Bhavesh Mohan Lal, Jawad Alrawabdeh, et al.
British Journal of Haematology|August 26, 2004
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulationMaurizio Zangari, Bart Barlogie, Elias Anaissie, et al.
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
British Journal of Haematology|November 9, 2018
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytesSyed J Mehdi, Sarah K Johnson, Joshua Epstein, et al.
European Journal of Haematology|April 24, 2024
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE studyHans C Lee, Karthik Ramasamy, Margaret Macro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple MyelomaCarolina Schinke, Pingping Qu, Syed J Mehdi, et al.
British Journal of Haematology|October 31, 2020
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximabFrits van Rhee, Jean-François Rossi, David Simpson, et al.
Pageof 28

Showing results (131-140 of 274) with videos related to

Sort By:
Pageof 28
Plos One|February 2, 2013
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsKatie Stone, Emily Woods, Susann M Szmania, et al.
American Journal of Hematology|August 7, 2024
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 24, 2025
The Involvement of PI3K-Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease-Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified SubtypesTomoka Haratake, Midori Filiz Nishimura, Asami Nishikori, et al.
Blood Cancer Journal|January 6, 2026
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myelomaToshali Pandey, Bhavesh Mohan Lal, Jawad Alrawabdeh, et al.
British Journal of Haematology|August 26, 2004
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulationMaurizio Zangari, Bart Barlogie, Elias Anaissie, et al.
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
British Journal of Haematology|November 9, 2018
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytesSyed J Mehdi, Sarah K Johnson, Joshua Epstein, et al.
European Journal of Haematology|April 24, 2024
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE studyHans C Lee, Karthik Ramasamy, Margaret Macro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple MyelomaCarolina Schinke, Pingping Qu, Syed J Mehdi, et al.
British Journal of Haematology|October 31, 2020
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximabFrits van Rhee, Jean-François Rossi, David Simpson, et al.
Pageof 28